Pursuant to Regulation 7(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Compliance Certificate jointly executed by the authorized representative of our share transfer agent viz. KFIN Technologies Private Limited and the Compliance Officer of Sequent Scientific Limited for the half year ended September 30, 2020. Kindly take the same on record.

Sequent Scientific Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Krunal ShahDesignation :- Company Secretary and Compliance Officer

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform you that India Ratings and Research has upgraded the Company's Long-Term Issuer Rating to 'IND A' from 'IND A-' while resolving the Rating Watch Evolving (RWE). The Outlook is Positive. We are enclosing herewith a Press Release titled 'Sequent Scientific's Credit Ratings upgraded by India Ratings and Research' issued by the Company in this regard. We request you to take the same on your record.

We refer to our announcement dated October 1, 2020 on proposed acquisition of 15% stake from Mr. Servatius Justinus Cornelius Maria Van Der Heijden in Fendigo BV through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company, we would like to inform you that the said transaction has been completed. On completion of the said transaction, Fendigo BV has become a Wholly Owned Subsidiary of the Company. We request you to take the above on your record.

Consolidation of Shareholding in Fendigo BV, Netherlands to make Fendigo BV a Wholly Owned Subsidiary of the Company Please find attached disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, consequent to entering into definitive agreement with Mr. Servatius Justinus Cornelius Maria Van Der Heijden for the acquisition of 15% stake from him in Fendigo BV through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company. On completion of the proposed acquisition, Fendigo BV will become a Wholly Owned Subsidiary of the Company. The said transaction is expected to be completed on or before October 31, 2020. We request you to take the above on your record.

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sequent Scientific Ltd

Notice is hereby given that pursuant to the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 read with Company''s Code of Conduct for Prohibition of Insider Trading, the Trading Window for all Connected Persons/Designated Persons and their immediate relatives to deal in the securities of the Company shall remain closed from Thursday, October 01, 2020 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ending on September 30, 2020. The date of Meeting of the Board of Directors of the Company at which the aforesaid Financial Results are to be approved, will be intimated to the Stock Exchanges in due course.

We refer to our announcement dated August 12, 2020 on the proposed sale of investments held by the Company in Strides Pharma Science Limited to Pronomz Ventures LLP and the outcome of Postal Ballot results dated September 18, 2020 filed with the Stock Exchanges, intimating receipt of shareholder approval for the proposed sale. Further to the above, we wish to inform you that the said sale of shares was consummated today. The proceeds of the sale (net of taxes) will be predominantly utilised to consolidate the Company's shareholding in Provet Veteriner Urunleri San. Ve Tic. A. S., Turkey (Provet) by acquiring 40% stake held by Dr. Husein Aydin in Provet, with the balance to be used to pare the outstanding debt of the Company. Post the acquisition of minority stake, which is expected to close on or before October 31, 2020, Provet will become a wholly owned subsidiary of the Company.

Please find attached a request letter dated September 24, 2020, received from the Promoter & Promoter Group seeking reclassification of shareholding from 'Promoter and Promoter Group' to 'Pubic' category. The list of Persons/ Entities seeking reclassification is listed in Annexure 1. The Promoters and Promoter Group are making the request consequent to the transfer of substantial shareholding and control over the Company to the Carlyle Group and they no longer are in control of the affairs of the Company. The request for reclassification will be considered by the Board of Directors and will be subject to approval of shareholders pursuant to Regulation 31A of the SEBI LODR.